150 related articles for article (PubMed ID: 32557780)
21. Prognostic value of tumor-infiltrating lymphocytes in DCIS: a meta-analysis.
Wu SL; Yu X; Mao X; Jin F
BMC Cancer; 2022 Jul; 22(1):782. PubMed ID: 35843951
[TBL] [Abstract][Full Text] [Related]
22. The immune microenvironment of breast ductal carcinoma in situ.
Thompson E; Taube JM; Elwood H; Sharma R; Meeker A; Warzecha HN; Argani P; Cimino-Mathews A; Emens LA
Mod Pathol; 2016 Mar; 29(3):249-58. PubMed ID: 26769139
[TBL] [Abstract][Full Text] [Related]
23. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
[TBL] [Abstract][Full Text] [Related]
24. An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctytes.
Kim A; Heo SH; Kim YA; Gong G; Jin Lee H
Am J Clin Pathol; 2016 Jul; 146(1):137-44. PubMed ID: 27402610
[TBL] [Abstract][Full Text] [Related]
25. MiRNA expression deregulation correlates with the Oncotype DX
Loudig O; Mitchell MI; Ben-Dov IZ; Liu C; Fineberg S
Breast Cancer Res; 2022 Sep; 24(1):62. PubMed ID: 36096802
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast.
Jia H; Zhao P; Chen Z; Wang G; Dong X; Xing X; Tan X; Wang C
Breast Cancer Res Treat; 2022 May; 193(1):111-120. PubMed ID: 35260954
[TBL] [Abstract][Full Text] [Related]
27. Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance.
Althobiti M; Aleskandarany MA; Joseph C; Toss M; Mongan N; Diez-Rodriguez M; Nolan CC; Ashankyty I; Ellis IO; Green AR; Rakha EA
Histopathology; 2018 Dec; 73(6):887-896. PubMed ID: 29947077
[TBL] [Abstract][Full Text] [Related]
28. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
[TBL] [Abstract][Full Text] [Related]
29. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
Solin LJ; Gray R; Baehner FL; Butler SM; Hughes LL; Yoshizawa C; Cherbavaz DB; Shak S; Page DL; Sledge GW; Davidson NE; Ingle JN; Perez EA; Wood WC; Sparano JA; Badve S
J Natl Cancer Inst; 2013 May; 105(10):701-10. PubMed ID: 23641039
[TBL] [Abstract][Full Text] [Related]
30. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
[TBL] [Abstract][Full Text] [Related]
31. The role of stromal immune microenvironment in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer.
Niwińska A; Olszewski WP
Breast Cancer Res; 2021 Dec; 23(1):118. PubMed ID: 34952631
[TBL] [Abstract][Full Text] [Related]
32. The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast.
Ubago JM; Blanco LZ; Shen T; Siziopikou KP
Am J Clin Pathol; 2019 Jul; 152(2):169-176. PubMed ID: 30984969
[TBL] [Abstract][Full Text] [Related]
33. The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12-gene DCIS score™ result.
Alvarado M; Carter DL; Guenther JM; Hagans J; Lei RY; Leonard CE; Manders J; Sing AP; Broder MS; Cherepanov D; Chang E; Eagan M; Hsiao W; Schultz MJ
J Surg Oncol; 2015 Jun; 111(8):935-40. PubMed ID: 26031501
[TBL] [Abstract][Full Text] [Related]
34. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB
Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854
[TBL] [Abstract][Full Text] [Related]
35. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
Campbell MJ; Baehner F; O'Meara T; Ojukwu E; Han B; Mukhtar R; Tandon V; Endicott M; Zhu Z; Wong J; Krings G; Au A; Gray JW; Esserman L
Breast Cancer Res Treat; 2017 Jan; 161(1):17-28. PubMed ID: 27785654
[TBL] [Abstract][Full Text] [Related]
36. Ductal carcinoma in situ of the breast: immune cell composition according to subtype.
Agahozo MC; van Bockstal MR; Groenendijk FH; van den Bosch TPP; Westenend PJ; van Deurzen CHM
Mod Pathol; 2020 Feb; 33(2):196-205. PubMed ID: 31375764
[TBL] [Abstract][Full Text] [Related]
37. Tertiary lymphoid structures in breast ductal carcinoma in situ correlate with adverse pathological parameters.
Zeng L; Koh VCY; Chen XY; Tan PH
Histopathology; 2023 Apr; 82(5):779-788. PubMed ID: 36635954
[TBL] [Abstract][Full Text] [Related]
38. Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer.
Wu J; Li X; Teng X; Rubin DL; Napel S; Daniel BL; Li R
Breast Cancer Res; 2018 Sep; 20(1):101. PubMed ID: 30176944
[TBL] [Abstract][Full Text] [Related]
39. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.
Hillyar C; Rizki H; Abbassi O; Miles-Dua S; Clayton G; Gandamihardja T; Smith S
Cureus; 2020 Apr; 12(4):e7552. PubMed ID: 32382456
[TBL] [Abstract][Full Text] [Related]
40. Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence.
Jirström K; Ringberg A; Fernö M; Anagnostaki L; Landberg G
Br J Cancer; 2003 Nov; 89(10):1920-6. PubMed ID: 14612904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
